These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 15815881)

  • 1. Vascular endothelial tissue factor pathway inhibitor kinetics in culture following exposure to DX-9065a--a selective and direct factor Xa inhibitor.
    Becker RC; Alexander JH; Li Y; Robertson T; Kunitada S; Spencer FA; Yang H; Harrington RA
    J Thromb Thrombolysis; 2004 Dec; 18(3):193-7. PubMed ID: 15815881
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Monitoring effects of direct FXa-inhibitors with a new one-step prothrombinase-induced clotting time (PiCT) assay: comparative in vitro investigation with heparin, enoxaparin, fondaparinux and DX 9065a.
    Graff J; Picard-Willems B; Harder S
    Int J Clin Pharmacol Ther; 2007 Apr; 45(4):237-43. PubMed ID: 17474542
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antithrombotic and hemorrhagic effects of DX-9065a, a direct and selective factor Xa inhibitor: comparison with a direct thrombin inhibitor and antithrombin III-dependent anticoagulants.
    Morishima Y; Tanabe K; Terada Y; Hara T; Kunitada S
    Thromb Haemost; 1997 Nov; 78(5):1366-71. PubMed ID: 9408021
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Global anticoagulant effects of a synthetic anti-factor Xa inhibitor (DX-9065a): implications for interventional use.
    Tobu M; Iqbal O; Ma Q; Schultz C; Jeske W; Hoppensteadt D; Lewis B; Fareed D; Fareed J
    Clin Appl Thromb Hemost; 2003 Jan; 9(1):1-17. PubMed ID: 12643318
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Species differences in anticoagulant and anti-Xa activity of DX-9065a, a highly selective factor Xa inhibitor.
    Hara T; Yokoyama A; Morishima Y; Kunitada S
    Thromb Res; 1995 Oct; 80(1):99-104. PubMed ID: 8578544
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Initial experience with factor-Xa inhibition in percutaneous coronary intervention: the XaNADU-PCI Pilot.
    Alexander JH; Dyke CK; Yang H; Becker RC; Hasselblad V; Zillman LA; Kleiman NS; Hochman JS; Berger PB; Cohen EA; Lincoff AM; Saint-Jacques H; Chetcuti S; Burton JR; Buergler JM; Spence FP; Shimoto Y; Robertson TL; Kunitada S; Bovill EG; Armstrong PW; Harrington RA;
    J Thromb Haemost; 2004 Feb; 2(2):234-41. PubMed ID: 14995984
    [TBL] [Abstract][Full Text] [Related]  

  • 7. DX-9065a inhibition of factor Xa and the prothrombinase complex: mechanism of inhibition and comparison with therapeutic heparins.
    Rezaie AR
    Thromb Haemost; 2003 Jan; 89(1):112-21. PubMed ID: 12540961
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antithrombotic effects of DX-9065a, a direct factor Xa inhibitor: a comparative study in humans versus low molecular weight heparin.
    Shimbo D; Osende J; Chen J; Robbins J; Shimoto Y; Kunitada S; Fuster V; Badimon JJ
    Thromb Haemost; 2002 Nov; 88(5):733-8. PubMed ID: 12428086
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of unfractionated heparin and a low molecular weight heparin (enoxaparin) on coagulant activity of cultured human endothelial cells.
    Martinez-Sales V; Vila V; Réganon E; Oms JG; Aznar J
    Haematologica; 2003 Jun; 88(6):694-9. PubMed ID: 12801846
    [TBL] [Abstract][Full Text] [Related]  

  • 10. DX-9065a, a direct inhibitor of factor Xa.
    Kaiser B
    Cardiovasc Drug Rev; 2003; 21(2):91-104. PubMed ID: 12847561
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of the novel direct factor Xa inhibitor DX-9065a on thrombin generation and inhibition among patients with stable atherosclerotic coronary artery disease.
    Becker RC; Alexander JH; Dyke C; Huang Y; Saint-Jacques H; Hasselblad V; Harrington RA; Bovill EG;
    Thromb Res; 2006; 117(4):439-46. PubMed ID: 15882894
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A synthetic selective inhibitor of factor Xa, DX-9065a, reduces monocyte chemoattractant protein-1 expression after ischemia-reperfusion injury in rat liver.
    Yamaguchi Y; Okabe K; Liang J; Matsumura F; Ohshiro H; Ishihara K; Matsuda T; Takeya M; Kuratsu JI; Mori K; Yamada S; Ogawa M
    Dig Dis Sci; 1999 Dec; 44(12):2568-76. PubMed ID: 10630515
    [TBL] [Abstract][Full Text] [Related]  

  • 13. First experience with direct, selective factor Xa inhibition in patients with non-ST-elevation acute coronary syndromes: results of the XaNADU-ACS Trial.
    Alexander JH; Yang H; Becker RC; Kodama K; Goodman S; Dyke CK; Kleiman NS; Hochman JS; Berger PB; Cohen EA; Lincoff AM; Burton JR; Bovill EG; Kawai C; Armstrong PW; Harrington RA;
    J Thromb Haemost; 2005 Mar; 3(3):439-47. PubMed ID: 15748230
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Factor Xa-inhibitor (DX-9065a) modulates the leukocyte-endothelial cell interaction in endotoxemic rat.
    Iba T; Kidokoro A; Fukunaga M; Fuse S; Suda M; Kunitada S; Hara T
    Shock; 2002 Feb; 17(2):159-62. PubMed ID: 11837793
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inactivation of factor Xa by the synthetic inhibitor DX-9065a causes strong anticoagulant and antiplatelet actions in human blood.
    Kaiser B; Jeske W; Walenga JM; Fareed J
    Blood Coagul Fibrinolysis; 1999 Dec; 10(8):495-501. PubMed ID: 10636461
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative effects of unfractionated heparin and low molecular weight heparin on vascular endothelial cell tissue factor pathway inhibitor release: a model for assessing intrinsic thromboresistance.
    Li Y; Rodriquez M; Spencer FA; Becker RC
    J Thromb Thrombolysis; 2002 Oct; 14(2):123-9. PubMed ID: 12714831
    [TBL] [Abstract][Full Text] [Related]  

  • 17. DX-9065a inhibits proinflammatory events induced by gingipains and factor Xa.
    Matsushita K; Imamura T; Tomikawa M; Tancharoen S; Tatsuyama S; Maruyama I
    J Periodontal Res; 2006 Apr; 41(2):148-56. PubMed ID: 16499718
    [TBL] [Abstract][Full Text] [Related]  

  • 18. DX-9065a, an orally active factor Xa inhibitor, does not facilitate haemorrhage induced by tail transection or gastric ulcer at the effective doses in rat thrombosis model.
    Tanabe K; Morishima Y; Shibutani T; Terada Y; Hara T; Shinohara Y; Aoyagi K; Kunitada S; Kondo T
    Thromb Haemost; 1999 May; 81(5):828-34. PubMed ID: 10365760
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characteristics of gastrointestinal absorption of DX-9065a, a new synthetic anticoagulant.
    Fujii Y; Takahashi M; Morita H; Kikuchi H; Aramaki Y; Amidon GL
    Drug Metab Pharmacokinet; 2007 Feb; 22(1):26-32. PubMed ID: 17329908
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tolerability, pharmacokinetics, and pharmacodynamics of DX-9065a, a new synthetic potent anticoagulant and specific factor Xa inhibitor, in healthy male volunteers.
    Murayama N; Tanaka M; Kunitada S; Yamada H; Inoue T; Terada Y; Fujita M; Ikeda Y
    Clin Pharmacol Ther; 1999 Sep; 66(3):258-64. PubMed ID: 10511061
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.